ReviewFrontiers in immunology2026
Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains a major therapeutic challenge, particularly when tumors resist targeted therapy or checkpoint blockade. Vaccinia virus (VV), historically used as a vaccine vector, is now being repurposed to selectively kill tumor cells while activating antitumor immunity. Beyond direct oncolysis, VV induces inflammatory cell death that recruits dendritic cells and reshapes tumor-immune interactions-a critical advantage in the immune-suppressed lung tumor microenvironment. This review highlights evidence from lung cancer models, detailing how specific VV strains modulate immunity and under which conditions these effects are therapeutically relevant. We discuss engineering strategies, from cytokine expression to enhanced costimulation, designed to convert "cold" tumors into responsive ones and enable rational combinations with checkpoint inhibitors. Early clinical data in non-small cell lung cancer are promising but also reveal key obstacles: inefficient systemic delivery and rapid immunosuppressive feedback within the tumor. Addressing these challenges will be essential for establishing VV as a robust systemic immunotherapy platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.